Table 1:
Demographic, Clinical and Treatment Characteristics among Survey Responders and Non-Responders
| Characteristic | Responders No. of Patients (%) | Non-Responders No. of Patients (%) | P |
|---|---|---|---|
| N | 32 | 48 | |
| Median Age at Diagnosis (yrs) | 51 | 54 | 0.646 |
| Gender | |||
| Male | 6 (19%) | 11 (23%) | 0.655 |
| Female | 26 (81%) | 37 (77%) | |
| Race | |||
| White | 29 (91%) | 42 (88%) | 0.361 |
| Black | 2 (6%) | 3 (6%) | |
| Hispanic | 0 (0%) | 3 (6%) | |
| Others | 1 (3%) | 0 (0%) | |
| HIV Status | |||
| Negative | 30 (94%) | 48 (100%) | 0.157 |
| Positive | 2 (6%) | 0 (0%) | |
| T Classification | |||
| T1 | 7 (22%) | 8 (17%) | 0.307 |
| T2 | 15 (47%) | 15 (31%) | |
| T3 | 6 (19%) | 17 (35%) | |
| T4 | 4 (12%) | 8 (17%) | |
| N Classification | |||
| N0 | 23 (72%) | 31 (65%) | 0.569 |
| N1 | 5 (16%) | 5 (10%) | |
| N2 | 3 (9%) | 7 (15%) | |
| N3 | 1 (3%) | 5 (10%) | |
| Radiotherapy Dose | |||
| < 55 Gy | 2 (6%) | 4 (8%) | 1.000 |
| 55 Gy | 26 (81%) | 39 (81%) | |
| > 55 Gy | 4 (12%) | 5 (10%) | |
| Radiotherapy Technique | |||
| AP/PA, then 3 field | 30 (94%) | 45 (94%) | 1.000 |
| Other | 2 (6%) | 3 (6%) | |
| Concurrent Chemotherapy | |||
| 5-FU/ cisplatin | 23 (72%) | 36 (75%) | 0.287 |
| 5-FU/ mitomycin C | 2 (6%) | 7 (15%) | |
| Capecitabine/ cisplatin | 6 (19%) | 3 (6%) | |
| 5-FU | 0 (0%) | 1 (2%) | |
| None | 1 (3%) | 1 (2%) | |
| Locoregional Failures | 3 (9%) | 6 (13%) | 0.734 |
| Colostomy | 3 (9%) | 6 (13%) | 0.734 |
HIV: Human Immunodeficiency Virus, AP: Antero-posterior, PA: Postero-anterior, 5-FU: 5-fluorouracil